<DOC>
	<DOC>NCT02545868</DOC>
	<brief_summary>This multicenter, randomized, open-label study will evaluate the immune response to vaccines (tetanus toxoid [TT], 23-valent pneumococcal polysaccharide vaccine [23-PPV], influenza vaccine, and keyhole limpet hemocyanin [KLH]) after administration of a dose of ocrelizumab (OCR) in participants with relapsing multiple sclerosis (RMS).</brief_summary>
	<brief_title>A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Diagnosis of RMS in accordance with the revised McDonald criteria Received at least 1 previous immunization against TT or tetanus and diphtheria (DT/Td) or tetanus, diphtheria, and acellular pertussis (DTaP/Tdap) Expanded disability status scale (EDSS) at baseline from 0 to 5.5 points, inclusive For sexually active participants with reproductive potential, use of reliable means of contraception Contraindications for or intolerance to oral or intravenous corticosteroids, including intravenous methylprednisolone, according to the country label Known presence of other neurologic disorders Treatment with any investigational agent within 24 weeks of screening or 5 halflives of the investigational drug, whichever is longer, or treatment with any experimental procedure for multiple sclerosis (MS)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>